SCMP Share Price

Open 10.40 Change Price %
High 10.75 1 Day 0.35 3.38
Low 10.32 1 Week 1.05 10.88
Close 10.70 1 Month 0.20 1.90
Volume 582137 1 Year -0.25 -2.28
52 Week High 17.55
52 Week Low 9.30
SCMP Important Levels
Resistance 2 11.10
Resistance 1 10.93
Pivot 10.59
Support 1 10.47
Support 2 10.30
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.24 -11.11%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
ORCL 50.30 8.57%
ORCL 50.30 8.57%
ORCL 50.30 8.57%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
GCFB 0.95 58.33%
FALC 0.38 52.00%
LOCM 0.09 50.00%
ENOC 7.65 41.67%
TROV 1.30 36.84%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AMRS 3.29 21.40%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
PTSX 0.12 -40.00%
More..

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP)

SCMP Technical Analysis 2.5
As on 22nd Jun 2017 SCMP Share Price closed @ 10.70 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 11.95 & Strong Buy for SHORT-TERM with Stoploss of 10.13 we also expect STOCK to react on Following IMPORTANT LEVELS.
SCMP Target for June
1st Target up-side 10.71
2nd Target up-side 11.21
3rd Target up-side 11.7
1st Target down-side 9.29
2nd Target down-side 8.79
3rd Target down-side 8.3
SCMP Other Details
Segment EQ
Market Capital 208269664.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.sucampo.com
SCMP Address
SCMP
4520 East-West Highway
3rd Floor
Bethesda, MD 20814
United States
Phone: 301-961-3400
Fax: 301-961-3440
SCMP Latest News
Interactive Technical Analysis Chart Sucampo Pharmaceuticals, Inc. ( SCMP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sucampo Pharmaceuticals, Inc.
SCMP Business Profile
Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company focused on research, discovery, development and commercialization of drugs based on ion channel activators known as prostones. The Company�s prostone-based compounds target the ClC-2 and big potassium (BK), ion channels. It is focused on developing prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other therapeutic applications of its drug technology. The Company�s products include AMITIZA (lubiprostone) and RESCULA (unoprostone isopropyl). AMITIZA is marketed in the United States for three gastrointestinal indications: chronic idiopathic constipation (CIC), in adults, irritable bowel syndrome with constipation (IBS-C), in adult women, and opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. RESCULA is a BK channel activator and has a different mechanism of action than other IOP lowering agents on the market.